Text Size

Tolerability and pharmacokinetics of intravitreal sirolimus

Mudumba S., Bezwada P., Takanaga H., Hosoi K., Tsuboi T., Ueda K., Kawazu K., Ali Y., Naor J.


  • 2012
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Pharmacology

  • Categories

    Preclinical development

  • Affiliations

    Pharmaceutical and Preclinical Development Department, Santen Incorporated, 2100 Powell Street, Emeryville, CA 94608, United States; Santen Pharmaceutical Co, Ltd., Ikoma-shi, Nara, Japan

Related Publications

Pyridylmethylthio derivatives as VEGF inhibitors. Part 1

Tajima H., Honda T., Kawashima K., Sasabuchi Y., Yamamoto M., Ban M., Okamoto K., Inoue K., Inaba T., Takeno Y., Aono H.


The growing burden of myopia in Europe: evidence from population-based cohorts

Tiemens A., van Hemert D.J., Lemma S.T., Quist S.W., Shi-van Wielink K., Agius D., Arnould L., Berendschot T.T.J.M., Beuse A., Bikbov M.M., Birtel J., Bountziouka V., Breteler M.M.B., Carbonaro F., Chakravarthy U., Coimbra R., de Vries V.A., Delcourt C., Farinha C., Finger R.P., Ghanbari M., Giannoulis D.A., Grohmann C., Hammond C.J., European Eye Epidemiology (E3) Consortium


Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes

Jovanović J., Zacharioudaki M., Kalatzi M., Papadakis G., Mulkalapalli N., Ernst F., de Milliano T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022